Charles River Laboratories (CRL) is higher today as the market digests a key corporate event: the planned CEO succession becomes effective on May 5, 2026 at the conclusion of the annual meeting, transitioning leadership from long-time CEO James C. Foster to COO Birgit Girshick. With the leadership timeline now reaching its effective date, investors are treating the transition as de-risking and are rotating back into the name ahead of the next fundamental catalyst.

CRL is scheduled to report results on May 7, 2026, putting focus on any commentary around bookings, demand stabilization, and whether the company reiterates or adjusts its 2026 framework. Into the print, incremental buying interest can be amplified by the stock’s relatively elevated short interest, which can tighten supply on up days and add to upside volatility if traders reduce exposure ahead of earnings.

The next two trading sessions will likely be driven less by the leadership change itself and more by whether management signals improving book-to-bill, better visibility in discovery and safety assessment, and the trajectory of margins versus the company’s stated 2026 expectations. Any change in tone on NHP availability and shipment timing, as well as updated capital allocation priorities following the annual meeting, could quickly reset expectations for the second half of 2026.